Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx: Why I Think The Worst Is Behind The Business
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx Q2 Earnings Call Highlights
GeneDx NASDAQ: WGS reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintaining its full-year 2026 outlook.
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $0.5 per share a year ago.
GeneDx: Why I Think The Selloff Went Too Far
GeneDx shares have collapsed 65% since November, but I assign a buy rating due to strong volume growth and undervaluation versus peers. Despite a 34% YoY volume increase, revenue growth lagged at 27% due to lower reimbursement rates from a shift to genome testing. WGS owns one of the largest rare disease genomic databases, creating a durable competitive advantage and potential for AI-driven value creation.
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.28 per share a year ago.
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings?
GeneDx heads into Q1 earnings results with strong exome and genome momentum, supported by expanding adoption and a growing rare-disease data advantage.
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Financial Contrast: GeneDx (NASDAQ:WGS) & Amarantus Bioscience (OTCMKTS:AMBS)
GeneDx (NASDAQ: WGS - Get Free Report) and Amarantus Bioscience (OTCMKTS:AMBS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Analyst Recommendations This is a summary of current ratings
100,284 Shares in GeneDx Holdings Corp. $WGS Bought by Capital International Investors
Capital International Investors acquired a new position in GeneDx Holdings Corp. (NASDAQ: WGS) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 100,284 shares of the company's stock, valued at approximately $10,805,000. Capital International Investors owned 0.35% of GeneDx
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.
